A data review and re-assessment of ovarian cancer serum proteomic profiling

[1]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[2]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[3]  Lance A Liotta,et al.  Genomics and proteomics: application of novel technology to early detection and prevention of cancer. , 2002, Cancer detection and prevention.

[4]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[5]  E. Petricoin,et al.  Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.

[6]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[8]  Daniel L Baker,et al.  Plasma lysophosphatidic acid concentration and ovarian cancer. , 2002, JAMA.

[9]  A. Vlahou,et al.  Proteomic approaches to biomarker discovery in prostate and bladder cancers , 2001, Proteomics.

[10]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[11]  Yan Xu,et al.  Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. , 2001, Analytical biochemistry.

[12]  L. Baudhuin,et al.  The Role and Clinical Applications of Bioactive Lysolipids in Ovarian Cancer , 2001, The Journal of the Society for Gynecologic Investigation: JSGI.

[13]  Y Chen,et al.  Evaluation of Plasma Lysophospholipids for Diagnostic Significance Using Electrospray Ionization Mass Spectrometry (ESI‐MS) Analyses , 2000, Annals of the New York Academy of Sciences.

[14]  M Markman,et al.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.

[15]  Jeffrey S. Morris,et al.  A comprehensive approach to the analysis of MALDI-TOF proteomics spectra from serum samples. , 2003 .

[16]  M. Verma,et al.  Proteomics for cancer biomarker discovery. , 2002, Clinical chemistry.

[17]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.